Contrast Agents and Radiopharmaceuticals – Market Insights – United States

The US contrast agent and radiopharmaceutical market will witness moderate growth over the forecast period. Growth will be driven by increasing PET and MRI procedure volumes, as well as broader adoption of imaging agents in CEUS and PET applications. However, market expansion will be constrained by ongoing concerns regarding gadolinium retention and radiation exposure associated with certain imaging modalities. In addition, the transition to value-based care will limit utilization of some procedures, favoring those that deliver superior diagnostic accuracy and visualization quality. Looking ahead, growth will be supported by the introduction of new contrast agents currently in development or clinical evaluation, as well as FDA approvals that expand the indications of existing agents.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for contrast agents and radiopharmaceuticals in the US from 2019 through 2035.

There has been a gradual increase in the number of FDA approvals for PSMA PET imaging agents.

Which PSMA PET imaging agents have received FDA approval?

What advantages do these agents provide?

What indications have been approved?

The FDA has expanded approval for the use of CEUS in radiology procedures.

What types of procedures does this approval extend to, and what additional procedures could potentially be approved in the future?

Which contrast agents have received FDA approval?

How will these FDA approvals affect the competitive landscape?

Investments in PET production, cyclotron networks, and theranostics infrastructure are becoming increasingly important competitive differentiators.

Which companies are expanding their PET and theranostics capabilities?

How will these investments improve radiopharmaceutical availability and distribution?

Looming concerns over the effects of gadolinium retention will negatively affect the use of contrast-enhanced MRI.

How are ACOs, health networks, and physicians responding to the recent findings on gadolinium retention?

What are the key differences between linear and macrocyclic GBCAs, and how will market demand for these products shift going forward?

Will other imaging modalities cannibalize contrast-enhanced MRI procedures?

Which companies (and associated products) will benefit from the shift to macrocyclic GBCAs?

Supply-chain resilience is becoming an important competitive consideration in the radiopharmaceutical and contrast agent market.

How are companies addressing radioisotope availability, contrast media supply risks, and radiopharmacy distribution needs?

How could tariffs, domestic production initiatives, and nuclear pharmacy networks affect future competitive positioning?